Adjuvant Molecular Hydrogen Therapy in SLE-associated Pulmonary Arterial Hypertension: A Case Report on Immunomodulatory Effects on Regulatory and Effector Lymphocytes
In Vivo · 2026
DOI: 10.21873/invivo.14220 ↗Kurz gefasst
Fallbericht in der Zeitschrift In Vivo, 2026. Verfasst von Chin Liu und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine, Tri-Service General Hospital, National Defense Medical University, Taipei, Taiwan, R.O.C. Hauptthemen laut MEDLINE: Lupus Erythematosus, Systemic, Hydrogen, Pulmonary Arterial Hypertension, Immunomodulation. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
BACKGROUND/AIM: Pulmonary arterial hypertension (PAH) is a significant and challenging complication for patients with systemic lupus erythematosus (SLE). It is thought to arise from immune dysregulation and vascular remodeling, ultimately leading to progressive right heart failure. Molecular hydrogen therapy, a selective antioxidant and anti-inflammatory agent, may modulate the immune responses seen in autoimmune diseases. This case report details the use of adjuvant hydrogen capsule therapy in a patient with SLE with PAH, suggesting its potential as a novel approach for this difficult clinical condition. CASE REPORT: A 42-year-old Taiwanese woman with SLE-PAH received hydrogen capsule therapy, during which serial immunophenotyping revealed dynamic changes in suppressive markers including programmed cell death protein 1 (PD1) and Fas cell surface death receptor (FAS), as well as regulatory T- and B-cell subsets. Notably, the populations of double negative and class-switched memory B-cells decreased during therapy, suggesting durable immune suppression. These results support the effect of hydrogen capsule therapy in achieving immune tolerance and inflammation modulation. CONCLUSION: This case study suggests that molecular hydrogen therapy may be a promising treatment for patients with SLE-PAH, particularly due to its immunomodulatory effects.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Internal Medicine, Tri-Service General Hospital, National Defense Medical University, Taipei, Taiwan, R.O.C.
- Department of Bioscience and Biotechnology, National Taiwan Ocean University, Keelung, Taiwan, R.O.C.
- Biotech Research and Innovation Centre, University of Copenhagen, Copenhagen, Denmark.
- The Finsen Laboratory, Rigshospitalet/National University Hospital, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark.
- Division of Cardiology, Department of Internal Medicine, Tri-Service General Hospital, National Defense Medical University, Taipei, Taiwan, R.O.C.
- School of Pharmacy, National Defense Medical University, Taipei, Taiwan, R.O.C.
Zitieren
APA
Liu, C., Lu, J. W., Wu, C. H., Ho, Y. J., Lui, S. W., Hsieh, T. Y., Wang, K. Y., & Liu, F. C. (2026). Adjuvant Molecular Hydrogen Therapy in SLE-associated Pulmonary Arterial Hypertension: A Case Report on Immunomodulatory Effects on Regulatory and Effector Lymphocytes. In Vivo. https://doi.org/10.21873/invivo.14220
Vancouver
Liu C, Lu JW, Wu CH, Ho YJ, Lui SW, Hsieh TY, et al. Adjuvant Molecular Hydrogen Therapy in SLE-associated Pulmonary Arterial Hypertension: A Case Report on Immunomodulatory Effects on Regulatory and Effector Lymphocytes. In Vivo. 2026. doi:10.21873/invivo.14220
BibTeX
@article{Liu2026,
author = {Liu, Chin and Lu, Jeng-Wei and Wu, Chun-Hsien and Ho, Yi-Jung and Lui, Shan-Wen and Hsieh, Ting-Yu and Wang, Kuang-Yih and Liu, Feng-Cheng},
title = {Adjuvant Molecular Hydrogen Therapy in SLE-associated Pulmonary Arterial Hypertension: A Case Report on Immunomodulatory Effects on Regulatory and Effector Lymphocytes},
journal = {In Vivo},
year = {2026},
doi = {10.21873/invivo.14220}
}
EUVIMED